523 research outputs found
Peritoneal Dialysis Fluid Concentrations of Linezolid in the Treatment of Vancomycin‐Resistant Enterococcus faecium Peritonitis
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90108/1/phco.23.12.1322.32702.pd
Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA
TOC summary: Diabetes was associated with increased risk for slow response and low rifampin levels
Relevance of biotic pathways to the long-term regulation of nuclear waste disposal. Topical report on reference eastern humid low-level sites
The purpose of the work reported here was to develop an order-of-magnitude estimate for the potential dose to man resulting from biotic transport mechanisms at a humid reference low-level waste site in the eastern US. A description of the reference site is presented that includes the waste inventories, site characteristics and biological communites. Parameter values for biotic transport processes are based on data reported in current literature. Transport and exposure scenarios are developed for assessing biotic transport during 500 years following site closure. Calculations of radionuclide decay and waste container decomposition are made to estimate the quantities available for biotic transport. Doses to man are calculated for the biological transport of radionucludes at the reference site after loss of institutional control. These dose estimates are compared to dose estimates we calculated for the intruder-agricultural scenarios reported in the DEIS for 10 CFR 61 (NRC). Dose to man estimates as a result of cumulative biotic transport are calculated to be of the same order-of-magnitude as the dose resulting from the more commonly evaluated human intrusion scenario. The reported lack of potential importance of biotic transport at low-level waste sites in earlier assessment studies is not confirmed by findings presented in this report. Through biotic transport, radionuclides can be moved to locations where they can enter exposure pathways to man
Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands
In the Federated States of Micronesia (FSM) and then the Republic of the Marshall Islands (RMI), levofloxacin pharmacokinetics (PK) were studied in children receiving directly observed once-daily regimens (10 mg/kg, age >5 years; 15–20 mg/kg, age ≤5 years) for either multidrug-resistant tuberculosis (MDR TB) disease or latent infection after MDR TB exposure, to inform future dosing strategies
Therapeutic drug monitoring and the conservative management of chronic tuberculous empyema: case report and review of the literature
Comparison of the ‘Denver regimen’ against acute tuberculosis in the mouse and guinea pig
Objectives: In this study, we sought to compare the sterilizing activity of human-equivalent doses of the ‘Denver regimen ’ against acute tuberculosis (TB) infection in the standard mouse model and in the guinea pig. Methods: Pharmacokinetic studies in guinea pigs were used to establish human-equivalent doses for rifampicin, isoniazid and pyrazinamide. Guinea pigs and mice were aerosol-infected with Mycobacterium tuberculosis CDC1551 and treatment was started 2 weeks later with rifampicin/isoniazid/pyrazinamide for up to 6 months. For the first 2 weeks of therapy, the dosing frequency was 5 days/week, and for the remaining period, twice weekly. Treatment was discontinued in groups of 30 mice and 10 guinea pigs at 5 months and at 6 months, and these animals were held for a further 3 months in order to assess relapse rates. Results: Guinea pig lungs became culture-negative after 3 months of predominantly twice-weekly treatment and relapse rates were 0 % (0/10) both after 5 months and after 6 months of treatment. In contrast, all mice remained culture-positive despite 6 months of the same treatment, and 93 % (28/30) and 69 % (20/29) of mice relapsed after treatment for 5 and 6 months, respectively. Conclusions: Treatment with rifampicin/isoniazid/pyrazinamide administered at human-equivalent doses is much more potent against acute TB infection in guinea pigs than in mice. Our findings have importan
The transcription factor STAT6 mediates direct repression of inflammatory enhancers and limits activation of alternatively polarized macrophages
The molecular basis of signal-dependent transcriptional activation has been extensively studied in macrophage polarization, but our understanding remains limited regarding the molecular determinants of repression. Here we show that IL-4-activated STAT6 transcription factor is required for the direct transcriptional repression of a large number of genes during in vitro and in vivo alternative macrophage polarization. Repression results in decreased lineage-determining transcription factor, p300, and RNA polymerase II binding followed by reduced enhancer RNA expression, H3K27 acetylation, and chromatin accessibility. The repressor function of STAT6 is HDAC3 dependent on a subset of IL-4-repressed genes. In addition, STAT6-repressed enhancers show extensive overlap with the NF-κB p65 cistrome and exhibit decreased responsiveness to lipopolysaccharide after IL-4 stimulus on a subset of genes. As a consequence, macrophages exhibit diminished inflammasome activation, decreased IL-1β production, and pyroptosis. Thus, the IL-4-STAT6 signaling pathway establishes an alternative polarization-specific epigenenomic signature resulting in dampened macrophage responsiveness to inflammatory stimuli
Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.
BACKGROUND: Evidence has existed for decades that higher doses of rifampin may be more effective, but potentially more toxic, than standard doses used in tuberculosis treatment. Whether increased doses of rifampin could safely shorten treatment remains an open question. METHODS/DESIGN: The HIRIF study is a phase II randomized trial comparing rifampin doses of 20 and 15 mg/kg/day to the standard 10 mg/kg/day for the first 2 months of tuberculosis treatment. All participants receive standard doses of companion drugs and a standard continuation-phase treatment (4 months, 2 drugs). They are followed for 6 months post treatment. Study participants are adults with newly diagnosed, previously untreated, smear positive (≥2+) pulmonary tuberculosis. The primary outcome is rifampin area under the plasma concentration-time curve (AUC0-24) after at least 14 days of study treatment/minimum inhibitory concentration. 180 randomized participants affords 90 % statistical power to detect a difference of at least 14 mcg/mL*hr between the 20 mg/kg group and the 10 mg/kg group, assuming a loss to follow-up of up to 17 %. DISCUSSION: Extant evidence suggests the potential for increased doses of rifampin to shorten tuberculosis treatment duration. Early studies that explored this potential using intermittent, higher dosing were derailed by toxicity. Given the continued large, global burden of tuberculosis with nearly 10 million new cases annually, shortened regimens with existing drugs would offer an important advantage to patients and health systems. TRIAL REGISTRATION: This trial was registered with clinicaltrials.gov (registration number: NCT01408914 ) on 2 August 2011
Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats.
Animal and clinical data show that high ratios of the area under the
concentration-time curve and the peak concentration in blood to the MIC of
fluoroquinolones for a given pathogen are associated with a favorable
outcome. The present study investigated whether improvement of the
therapeutic potential of ciprofloxacin could be achieved by encapsulation
in polyethylene glycol (PEG)-coated long-circulating sustained-release
liposomes. In a rat model of unilateral Klebsiella pneumoniae pneumonia
(MIC = 0.1 microg/ml), antibiotic was administered at 12- or 24-h
intervals at twofold-increasing doses. A treatment period of 3 days was
started 24 h after inoculation of the left lung, when the bacterial count
had increased 1,000-fold and some rats had positive blood cultures. The
infection was fatal within 5 days in untreated rats. Administration of
ciprofloxacin in the liposomal form resulted in delayed ciprofloxacin
clearance and increased and prolonged ciprofloxacin concentrations in
blood and tissues. The ED(50) (dosage that results in 50% survival) of
liposomal ciprofloxacin was 3.3 mg/kg of body weight/day given once daily,
and that of free ciprofloxacin was 18.9 mg/kg/day once daily or 5.1
mg/kg/day twice daily. The ED(90) of liposomal ciprofloxacin was 15.0
mg/kg/day once daily compared with 36.0 mg/kg/day twice daily for free
ciprofloxacin; 90% survival could not be achieved with free ciprofloxacin
given once daily. In summary, the therapeutic efficacy of liposomal
ciprofloxacin was superior to that of ciprofloxacin in the free form.
PEG-coated liposomal ciprofloxacin was well tolerated in relatively high
doses, permitting once daily administration with relatively low
ciprofloxacin clearance and without compromising therapeutic efficacy
- …